EICHOR
● Not Yet Recruiting
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
Condition: Castration-resistant Prostate Cancer · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
About this study
This study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.
This description comes directly from the study's public registry record.
Talk to the study team
Sa Xiao, PHD · 15013238943 · xiaosa@baili-pharm.com
Always discuss trial participation with your own doctor first.
Locations (2)
| The First Medical Center of Chinese PLA General Hospital | Beijing, Beijing Municipality, China | — |
| The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) | Shanghai, Shanghai Municipality, China | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07641855